|
Publications:
Plump, D.; Haponil, E.F.; Katz, R.S.; Tipton-Donovan, A.:
Primary Adamantinoma of Rib: Thoracic Manifestations of a Rare Bone Tumor.
South Med J, March 1986; 79 (3): 352-5.
Berzon, D.M.; Menkes, H.; Dannenberg, A.M. Jr.; Gertner, A.;
Terry, P.; Plump, D.; Bromberger-Barnes, B.: Interstitial Fibrosis and
Collateral Ventilation. J Appl Physiol, July 1986; 61 (1):
300-3.
Rock, P.; Silverman, H.; Plump, D.; Kecala, Z.; Smith, P.;
Michael Jr., Summer, W.: Efficacy and Safety of Naloxone in Septic Shock.
Critical Care Med, Jan 1985; 13 (1): 28-33
Plump, D.H.; Haponik, E.F.: Streptococcus Milleri Empyema.
South Med J, Oct. 1983; 76 (10): 1321-2.
Presentations:
Response of the Lung Periphery to Arachodonic Acid: Residual
Response after Vagal and Cyclocxygenase Blockade, D.H. Plump, R.J. Traystman,
H.A. Mendes, A.R. Gertner, B. Bomberger, P.B. Terry and D.M. Berzon, Scientific
Session, American Lung Association/American Thoracic Society, Annual Meeting,
May 1982
Clinical Chest Rounds; Scientific Session, American Lung
Association/American Thoracic Society Annual Meeting, Las Vegas, Nevada, May
10, 1988
Clinical Trials:
A 12-week, treatment, multi-center,
randomized, double-blind, placebo-controlled, parallel-group
study to assess the efficacy and safety of once daily
indacaterol in patients with chronic obstructive pulmonary
disease. [Novartis Pharmaceuticals Corporation], January, 2010,
ongoing. Sub-Investigator.
A randomized, double-blind,
placebo-controlled study evaluating the efficacy, safety, and
tolerability of 2 doses of Aclidinium Bromide compared with
placebo for 12 weeks in patients with moderate to severe, stable
chronic obstructive pulmonary disease followed by a 40-week
evaluation of the two Aclidinium Bromide doses. [Forest Research
Institute, Inc.], November, 2009, ongoing. Principal
Investigator.
A randomized, double-blind, controlled,
parallel group, 12-week treatment study to compare the efficacy
and safety of the combination of indacaterol 150
Fg
once daily with open label tiotropium 18
Fg
once daily versus open label tiotropium 18
Fg
once daily in patients with moderate-to-severe chronic
obstructive pulmonary disease.
[Novartis Pharmaceuticals Corporation], April, 2009, ongoing.
Principal Investigator.
|